

Illustration of TLX591-Tx
Lutetium (^{177}Lu) rosopatomab tetraxetan



TLX591-Tx ProstACT Global Phase 3 study (NCT06520345)

Part 1 results: Safety and dosimetry

March 10, 2026

ASX: TLX | NASDAQ: TLX



Forward looking statements

This presentation should be read together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website.

The information contained in this presentation is not intended to be an offer for subscription, invitation or recommendation with respect to shares of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this presentation are subject to change without notification. To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this presentation, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in this presentation.

This presentation may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “believe”, “outlook”, “forecast” and “guidance”, or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Telix’s actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress, completion and results of Telix’s preclinical and clinical trials, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix’s product candidates, including the planned NDA resubmission for TLX101-Px and the planned BLA resubmission for TLX250-Px, manufacturing activities and product marketing activities; Telix’s sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix’s product candidates, if or when they have been approved; Telix’s ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix’s business; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.

This presentation also contains estimates and other statistical data made by independent parties and by Telix relating to market size and other data about its industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such data and estimates. In addition, projections, assumptions and estimates of Telix’s future performance and the future performance of the markets in which it operates are necessarily subject to a high degree of uncertainty and risk.

Telix’s first generation PSMA-PET imaging product, gallium-68 (⁶⁸Ga) gozetotide injection (also known as ⁶⁸Ga PSMA-11 and marketed under the brand name Illucix®), has been approved in multiple markets globally. Gozellix® (kit for the preparation of gallium-68 (⁶⁸Ga) gozetotide injection) has been approved by the U.S. FDA. Telix’s osteomyelitis (bone infection) imaging agent, technetium-99m (^{99m}Tc) besilesomab (marketed under the brand name Scintimun®) is approved in 32 European countries and Mexico. Telix’s miniaturized surgical gamma probe, SENSEI®, for minimally invasive and robotic-assisted surgery, is registered with the FDA for use in the U.S. and has attained a Conformité Européenne (CE) Mark for use in the EEA. Registrations vary country to country. Refer to your local approved label or regulatory authority status for full information.

No other Telix drug or device has received marketing authorization in any jurisdiction. Any other Telix drug or device that is discussed in this presentation, including Zircaix and Pixlara, is investigational or under development and not approved by any regulatory authority. The efficacy or safety profile of any unapproved drug or device has not been determined by any regulatory authority. In addition, Zircaix and Pixlara brand names and launch are subject to final regulatory approval.

All trademarks and trade names referenced in this press release are the property of Telix Pharmaceuticals Limited (Telix) or, where applicable, the property of their respective owners. For convenience, trademarks and trade names may appear without the ® or ™ symbols. Such omissions are not intended to indicate any waiver of rights by Telix or the respective owners. Trademark registration status may vary from country to country. Telix does not intend the use or display of any third-party trademarks or trade names to imply any affiliation with, endorsement by, or sponsorship from those third parties.

©2026 Telix Pharmaceuticals Limited. All rights reserved.

Presenters



Dr. Christian Behrenbruch

Managing Director and
Group CEO



David N. Cade, MD

Telix Group Chief
Medical Officer



Pedro C. Barata, MD*

Medical Oncologist, University
Hospitals Seidman Cancer Center

Associate Professor of Medicine, Case
Western Reserve University School of
Medicine, Cleveland

Director of the Clinical Genitourinary
Medical Oncology Research Program
and the Co-Leader of the Genitourinary
Disease Team

**ProstACT Global Steering Committee
Member and Investigator**



*Independent expert speaker, not an employee of Telix.
Views are speaker's own.



Introductory remarks

ProstACT Global Phase 3 (Part 1 Lead-in): Key findings

Primary and secondary endpoints: Safety and dosimetry


- ✓ **Study objectives met:** Confirmed safety, pharmacokinetics, dosimetry across cohorts
- ✓ **No new safety signals:** Hematologic events transient and manageable
- ✓ **Tolerability profile** supported by dosimetry and low-grade non-hematologic events
- ✓ Lesion dosimetry indicates no difference in **absorbed dose profile** across cohorts
- ✓ **No adverse drug-drug interactions** observed in TLX591-Tx combinations

Demonstrates feasibility of integrating TLX591-Tx with contemporary, global standards of care

TLX591-Tx is a novel therapy candidate for prostate cancer

Differentiated radiopharmaceutical using an antibody (mAb) to target PSMA¹

TLX591-Tx:
Lutetium (¹⁷⁷Lu)
rosopatamab tetraxetan



Radio antibody-drug conjugate (rADC) approach addresses key unmet needs²⁻⁵


1. **Patient friendly two-dose regimen:** Supports compliance to treatment and ease of integration with standard of care (SOC)
2. **Safety and tolerability profile:** Low radiation to salivary glands and kidneys, transient and manageable hematologic profile
3. **Internalization and prolonged retention:** Delivering a payload to the tumor, potentially maximizing cell killing effect
4. **Supply, access, and radiation protection:** Potential real-world advantages from lower administered activity (76 mCi per dose)

Differences described are not derived from head-to-head clinical studies, cross-trial comparison should be interpreted as not being definitive.

TLX591-Tx rADC versus 1st generation small molecule RLT

Key differences underpin PSMA tumor targeting, internalization, and prolonged retention

	rADC	1 st generation RLT ⁵
Radiopharmaceutical description	TLX591-Tx ¹⁻⁴	Small Molecule
Recommended dose	2 x 76 mCi (14 days apart)	6 x 200 mCi (6 weeks apart) ⁶
Molecular weight (MW)	Antibody Large (mw ~150,000)	Small molecule (mw ~1,200)
Terminal half-life (t _{1/2})	5.6 days	1.7 days
Off-target organ exposure	Liver, spleen	Salivary glands, kidneys, GI ⁷ tract, other sites
Route of excretion	Hepatobiliary (liver)	Renal (kidneys)



Differences described are not derived from head-to-head clinical studies, cross-trial comparison should be interpreted as not being definitive.

Patient representative scans – individual results may vary.

1. Sartor O, et al. Presented at: American Society of Clinical Oncology Annual Meeting 2024; TPS5115.
2. Sun M, et al. *Curr Oncol Rep*. 2021.
3. Data on file. Telix Pharmaceuticals Limited.
4. Tagawa ST et al. *Cancer*. 2019.

5. Radio-ligand therapy.
6. Lu177-PSMA617. Prescribing information. 2022. Novartis Pharmaceuticals AG. Administered every 6 weeks for up to 6 treatments, solution for injection contains 200 mCi (7.4 GBq) at time of use.
7. Gastrointestinal.



Study design and patient population




ProstACT Global study design reflects global clinical practice

Allows investigator to combine TLX591-Tx with ARPI or docetaxel

Typical clinical practice following disease progression on first ARPI

Predominantly ARPI Switch²

Predominantly Docetaxel^{3,4,5,6,7,8}



U.S.

- Largest prostate cancer market¹
- NCCN Guidelines[®] allow either ARPI or docetaxel⁹
- **Real-world analysis indicates 57% of patients** receive another ARPI as next therapy²

Rest of World

- Guidelines support docetaxel post-progression on first ARPI

ProstACT Global Phase 3 current status


Part 2 approved in select jurisdictions and enrolling patients

Part 1 complete, prerequisite for progression to Part 2 in U.S.¹



ClinicalTrials.gov ID:
[NCT06520345](https://clinicaltrials.gov/ct2/show/study/NCT06520345).

- Enrolling in Australia, New Zealand, & Canada following IDMC⁴ review
- Regulatory approvals obtained allowing study start in China, Singapore, South Korea, Japan⁵, Türkiye, & UK




Part 1 enrolled 36 patients each with one prior ARPI treatment

All patients received two doses of TLX591-Tx

Key observations

- No treatment-related deaths
- 32 patients remain alive
- 26 patients continuing on the study



Part 1: Baseline demographics and prior treatments¹

Majority of patients (n=36) are 2L mCRPC

Baseline age demographics

Slightly older patient population compared to other ¹⁷⁷Lu-PSMA trials²

- Mean age: 75 years
- Median age: 77 years
- Age range: 59 – 88 years

Prior treatments	
Setting of 1 st ARPI indication, n (%)	
mCSPC ³	10 (28)
mCRPC 1L	26 (72)
Prior ARPI therapy, n (%)	
Abiraterone	10 (28)
Apalutamide	3 (8)
Darolutamide	6 (17)
Enzalutamide	17 (47)
Prior taxane treatment in mCSPC, n (%)	
Yes	9 (25)
No	27 (75)

Other prognostic factors	
PSA ⁴ (ng/dL) at baseline medium range, n	
Mean	60.3
Median	18.2
ECOG performance status, n (%)	
0	19 (53)
1	17 (47)
Sites of metastases, n (%)	
Lymph Node	14 (39)
Bone (Skeletal)	17 (47)
Viscera	13 (36)

1. ProstACT Global Part 1 data on file. Telix Pharmaceuticals.
2. Morris et al. *Lancet* 2024.
3. Metastatic castration sensitive prostate cancer.

4. Prostate-specific antigen.



Safety



Acceptable safety profile confirmed with no new safety signals

Non-hematologic events were low grade, hematologic events were transient and manageable

Key observations

Treatment emergent adverse events (TEAE)

- Most prevalent non-hematologic adverse events were fatigue (53%), nausea (28%) and dry mouth (25%)
- Almost all TLX591-Tx related non-hematologic events were grade 1 or grade 2²

Hematologic events: In line with profile expected for this class of therapy

- **Grade 3** thrombocytopenia 5/36 (14%) and neutropenia 8/36 (22%) events in line with profile expected for this class of therapy; single Grade 3 anemia
- **Grade 4** thrombocytopenia 11/36 (31%) and neutropenia 9/36 (25%)



Therapeutics

1. ProstACT Global Part 1 data on file. Telix Pharmaceuticals.
2. One grade 3 dizziness was considered treatment-related.
3. White blood cell.


ProstACT Global Part 1 (safety TEAE)¹

Adverse Event	Grade 1	Grade 2	Grade 3	Grade 4	Total (n)	% of N=36
Non-hematologic events						
Fatigue	10	7	2	0	19	53
Nausea	5	4	1	0	10	28
Dry mouth	9	0	0	0	9	25
Diarrhea	5	3	0	0	8	22
Back pain	4	3	1	0	8	22
Headache	4	1	0	0	5	14
Hematologic events						
Thrombocytopenia	6	6	5	11	28	78
Neutropenia	2	4	8	9	23	64
Anemia	5	10	1	0	16	44
WBC ³ decrease	0	4	6	5	15	42
Lymphopenia	0	5	8	7	20	56

Hematological profile transient and consistent across cohorts

Platelet counts recovered consistently in all three cohorts at ~15 days post nadir

TLX591-Tx (2 doses at 76 mCi each)






Dosimetry




Pharmacokinetic profile driven by TLX591-Tx residence time

Demonstrates sustained activity, consistent across cohorts¹

Blood radioactivity
Concentrations-Time Profile



Lesion activity
Concentrations-Time profile




Key observations

- **Predictable PK profile:** Low inter-patient variability supports reliable dosing, streamlined clinical development
- **No evidence of drug-drug interaction:** Exposure and washout kinetics were consistent across cohorts
- **Sustained tumor retention:** Lesion activity concentrations remained detectable through 15 days, demonstrating prolonged radiation exposure to the tumor

Organ radiation exposure is well below established safety limits

Low radiation to salivary glands and kidneys supports tolerability profile



Key observations

- Liver (clearance organ), colon, rectum, spleen, kidney and red marrow mean absorbed dose (Gy) below the threshold for known radiation injury^{2,3}
- Dose to organs at risk consistent with Phase 1 SELECT data

Lesion dosimetry confirmed TLX591-Tx uptake in tumors

Meaningful absorbed dose across lesion locations and consistent across cohorts¹

Tumor dose (Gy) after the administration of TLX591-Tx in 2 doses of 2812 MBq (76 mCi) 14 days apart

Tumor Sites	Mean	Median	Min	Max	SD
All lesions (n=132)	4.83	2.84	0.28	49.59	6.91
Bone (n=122)	5.00	2.92	0.28	49.59	7.14
Lymphatic nodes (n=8)	2.01	2.15	1.02	2.89	0.53
Soft tissue (n=2)	5.73	5.73	3.27	8.20	2.46


The mean tumor volume by site was 13.47 ± 16.22 mL for bone, 13.52 ± 15.21 mL for lymphatic tissue and 9.87 ± 0.15 mL for soft tissue lesions.

1. ProstACT Global Part 1 data on file. Telix Pharmaceuticals.

Patient case: TLX591-Tx plus abiraterone

64-year-old patient with metastatic disease in lymph nodes¹


SPECT TLX591-Tx biodistribution: Single dose Distribution of TLX591-Tx over 15 days²



Patient case: TLX591-Tx sequenced with docetaxel

83-year-old patient with bony metastatic lesions¹

SPECT TLX591-Tx biodistribution: Single dose Distribution of TLX591-Tx over 15 days²





Summary



Summary: ProstACT Global Part 1

TLX591-Tx plus standard of care has acceptable safety and favorable dosimetry¹

- **Acceptable and manageable safety and tolerability** demonstrated across combination cohorts, no new safety signals or adverse drug-drug interactions
- **Low radiation exposure to salivary glands and kidneys** support acceptable tolerability profile
- **Pharmacokinetics supports sustained activity at 15 days**, imaging shows prolonged tumor retention
- **Patient friendly two dose regimen** supports compliance to treatment and ease of integration with standard of care (SOC)




Illustration of TLX591-Tx
Lutetium (^{177}Lu) rosopatomab tetraxetan

Investor Relations Contacts:

Kyahn Williamson (Global)
SVP Investor Relations and Corporate Communications
kyahn.williamson@telixpharma.com

Telix Investor Relations (U.S.)
Ms. Annie Kasparian
Director Investor Relations and Corporate
Communications
annie.kasparian@telixpharma.com

Telix Investor Relations (Australia)
Ms. Charlene Jaw
Associate Director Investor Relations
charlene.jaw@telixpharma.com

